



WELCOME

Sustainability is about operating responsibly to deliver long-term impact. At Abbott, we're strengthening the resilience of our company so we can continue to shape the future of healthcare — to help more people live better, healthier lives.

In this report summary, we detail our progress against the goals of our 2030 Sustainability Plan. All financial information is stated in U.S. dollars. All data reflects Abbott's activities, with a focus on 2022 results. The boundary of our reporting, unless otherwise noted, is all activities under Abbott's global, operational control, as consolidated in our financial reporting. Common rounding convention has been utilized throughout the report, see 2022 Global Sustainability Report appendix for detailed data. All Abbott trademarks appear in italics throughout this report. Our detailed annual sustainability performance can be found in our [Global Sustainability Report](#).

On the cover: In 2021, Abbott established an ongoing partnership with Real Madrid and the Real Madrid Foundation, working together to educate, support, nourish, and develop kids around the world across all geographies, cultures, and backgrounds. In July 2022, we hosted a youth soccer clinic in Stockton, California, reinforcing the importance of regular exercise as part of a healthy life.

TABLE OF CONTENTS

About		Protect a Healthy Environment	23
Chairman and CEO Letter	03	Energy and Emissions	24
About Abbott	04	Protecting Water Resources	25
Realizing Our Purpose	05	Waste Management	25
Our 2030 Sustainability Plan	06	Packaging	26
Progress Against Our 2030 Sustainability Plan	07	Responsible Sourcing and Product Stewardship	26
Supporting Our Global Communities	15		
		Quality Management	27
Innovate for Access and Affordability	16	Create a Resilient, Diverse, and Responsible Supply Chain	28
Access and Affordability Through Product Innovation	16	Designing for Supply Chain Resilience	28
Transform Care for Chronic Disease, Malnutrition, and Infectious Disease	17	Guiding Responsible Suppliers	28
Advance Health Equity Through Partnerships	18	Supplier-Sustainability-Risk Due Diligence Program	29
		Strengthening the Supply Chain	29
Responsibly Connect Data, Technology, and Care	19	Ethics and Compliance	30
The Principles of Data Use	19		
Connected-Care Technologies	19	Sustainability Reporting	31
Build the Diverse, Innovative Workforce of Tomorrow	20		
Attracting the Best Talent	20		
Employee Well-Being	21		
Diversity, Equity, and Inclusion	21		
Employee Health and Safety	22		
Human Rights	22		

A Caution Concerning Forward-Looking Statements: Some statements in this report may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

DEAR ABBOTT STAKEHOLDER

This is Abbott's 135th anniversary year, which speaks to our relationship to sustainability. We understand, and deeply value, the stewardship mentality and commitment needed to support resilience and thriving for the long term.

That history, and the culture that has made it possible, were critical to Abbott's successful navigation of the global environment over the three years of the COVID-19 pandemic. Our company was built for moments like this one. The result of our long experience and deep expertise was the rapid creation of 12 different COVID-19 diagnostic tests to help the world meet its most severe health challenge in a century.

While COVID-19 is moving to the endemic level, it leaves us a health agenda for the future. The pandemic forcefully demonstrated the long-standing challenges in our global health systems. Disparities in access to care widened dramatically and undeniably, underscoring the need for action to close these gaps.

Addressing this need is the primary focus of Abbott's 2030 Sustainability Plan, which we created before COVID-19 highlighted it so vividly. While Abbott is advancing its performance across the ESG spectrum, we recognize that our greatest opportunity to impact the world's future lies in improving the health of the greatest number of people.

To do so, we're very consciously innovating for access and affordability. We've implemented Design Principles to make our new products and

technologies easier to use and available to more of the people who need them in more places around the world. This is how we intend to meet our ambitious goal of helping 3 billion people annually by 2030, an increase of 50% over the course of our Plan.

Our aim is not just to serve more people, but to do so better than ever before. Our Abbott Customer Pledge commits us to "make our products and services as if they're for our own families." Abbott people take that obligation seriously and personally.

At Abbott, we carry our purpose of helping people live fuller lives through better health into our efforts to aid communities in need around the world, for example:

- For more than two decades, we've partnered with the government of Tanzania to strengthen the country's healthcare system.
- Our *Future Well* Communities program works with partners in Stockton, California to remove barriers that prevent people with diabetes from living healthy lives.
- And we've provided almost \$16 million in aid to people impacted by the war in Ukraine.

It's this belief in our purpose that keeps our company strong and growing through generations of success. We're inspired by our vision of a better, healthier future, and determined to keep Abbott at the forefront of healthcare for the next 135 years.

Thank you for your support of our work.



Robert B. Ford

CHAIRMAN AND CHIEF EXECUTIVE OFFICER
JUNE 22, 2023



ABOUT ABBOTT

Abbott is dedicated to helping people live their best lives through better health.

We believe a sustainable future starts with health.

For 135 years, we've been improving people's health at all ages and stages of life — tackling some of the world's most pressing health problems with our innovative products and technologies.

TODAY, OUR PORTFOLIO INCLUDES:



Diagnostics systems and tests performed in laboratories, at the patient's bedside, in doctors' offices, or the home that provide information to support better and more timely decisions for people and their doctors.



Medical devices that use the most advanced technologies to keep hearts and arteries healthy, treat chronic pain and movement disorders, and give people with diabetes more freedom and less pain.



Medicines that help people in emerging markets get and stay healthy.



Nutrition products that build and maintain health and strength from infancy onward.

2022 ABBOTT IN NUMBERS

\$43.7B

total 2022 revenue

51

years of increasing dividends

160+

countries where Abbott is present

8.5%

dividend increase in 2022

115,000

employees

\$2.9B

investment in R&D

RECOGNIZED PERFORMANCE

Wall Street Journal Management Top 250 Companies

Ranked #36 with "5 star" ratings in innovation and social responsibility

Newsweek America's 2023 Most Responsible Companies

#12 out of 500 companies

S&P Global ESG Corporate Sustainability Assessment (CSA)

Highest score of any company in the Healthcare Equipment and Supplies industry (December 2022)

DiversityInc's Top 50 Companies for Diversity

19 consecutive years in 2022

Fast Company's Most Innovative Companies in Sports in 2022

2022 Prix Galien Golden Jubilee Award

Abbott's *FreeStyle Libre* was named the best medical technology in the last 50 years by the Galien Foundation

REALIZING OUR PURPOSE

Our goal is simple: to help people live their fullest lives through better health.

OUR CORE VALUES

Four core values guide how we support this purpose every day:



Pioneering

We see needs first and deliver game-changing solutions. We create new technologies and products to help people live fuller lives through better health, and we bring that same spirit of innovation to everything we do as a company.



Caring

We treat the people who depend on us as if they were our family. Dr. Wallace Abbott began our company to provide better care to his own patients. That spirit still guides everything we do.



Achieving

We focus relentlessly on delivering for our stakeholders. Abbott is all about execution. Millions of people around the world depend on us in vital ways. We're committed to honoring that trust.



Enduring

We know that everything we do today should contribute to a stronger tomorrow. Because our work is so important to so many, it's up to us to help ensure that this company keeps thriving. That's why we think and act for the long term. We intend to be here for the next 135 years, bringing all the benefits that Abbott creates to all the people who need them.

OUR IMPACT IN 2022

>2B

lives improved due to Abbott products and services¹

\$30.6M

in products donated

\$27.2M

donated through the Abbott Fund, Abbott's philanthropic foundation

41%

of global management positions filled by women

5%

absolute reduction in Scope 1 and 2 emissions in 2022 (vs. 2018 baseline)

29M

pounds of packaging impacted through sustainable design programs

¹Total number of lives improved was adjusted for indirect overlap between businesses using a binomial probability model, and only adjusted for direct overlap within a business where data is currently available to support the adjustment.

OUR 2030 SUSTAINABILITY PLAN

Launched in 2020, our 2030 Sustainability Plan priorities and supporting goals focus on helping more people, in more places, live their healthiest possible lives.

They also guide us in embedding sustainability into everything we do to help ensure that Abbott remains relevant and resilient into the future.

Our goal is to improve the lives of 3 billion people a year by decade's end — reaching 1 billion more than we did in 2020.

OUR PRIORITY

INNOVATE FOR ACCESS AND AFFORDABILITY

Make **access and affordability** core to new product innovation.

Transform care for chronic disease, malnutrition, and infectious diseases.

Advance **health equity** through partnership.

SUSTAINABILITY IN EVERYTHING WE DO

Build the diverse, **innovative workforce** of tomorrow.

Responsibly **connect data,** technology, and care.

Create a resilient, diverse, and responsible **supply chain.**

Protect a **healthy environment.**

PROGRESS AGAINST OUR 2030 SUSTAINABILITY PLAN

INNOVATE FOR ACCESS AND AFFORDABILITY

Central to the success of our Sustainability Plan is our focus on innovating for access and affordability. Our 2030 goals guide the delivery and democratization of these life-changing technologies and products.

2030 GOAL

Make access and affordability core to new product innovation

Integrate access and affordability and data insights as design principles into our R&D work and portfolio.

PROGRESS AND NOTES

- More than 2 billion lives improved² due to Abbott's products and services.
- Integrated our Innovate for Access and Affordability Design Principles into our R&D processes across all businesses, evolving the way we develop and bring technologies to people who need them.
- Introduced the *FreeStyle Libre 3* system in the United States, the most accurate 14-day continuous glucose monitor. Designed for access and affordability, the *FreeStyle Libre 3* system will be available at the same price as previous versions, which is about one-third the cost of other competing continuous glucose monitoring systems available today.
- Launched an improved version of our *NeuroSphere myPath* digital health app, helping doctors more easily access data and improve their patients' response to therapy.
- The FDA approved the *Eterna* spinal cord stimulation system, the smallest implantable, rechargeable spinal cord stimulator currently available for the treatment of chronic pain. *Eterna* can be recharged less than five times a year under normal use, making it the lowest recharge burden platform available.
- The FDA approved an expanded indication for the *CardioMEMS* HF System, meaning that an additional 1.2 million U.S. patients who have earlier-stage heart failure have the potential to use advanced monitoring with the *CardioMEMS* sensor, which provides an early warning system for worsening heart failure.

²Total number of lives improved was adjusted for indirect overlap between businesses using a binomial probability model, and only adjusted for direct overlap within a business where data is currently available to support the adjustment.

INNOVATE FOR ACCESS AND AFFORDABILITY (CONTINUED)

2030 GOAL

Transform care for chronic disease, malnutrition, and infectious diseases

Support global efforts to address noncommunicable diseases, including diabetes and cardiovascular disease.

- Innovate to transform the standard of care for diabetes and support efforts to bend the diabetes curve through innovative technology, prevention and education, early diagnosis, treatment, and nutrition.
- Deliver breakthrough technologies, improve clinical outcomes, and impact the lives of people with or at risk of cardiovascular disease.

Deliver scalable, integrated solutions to help reduce preventable deaths and infectious diseases (malaria, hepatitis B/C, HIV, COVID-19, and others) with diagnostics, treatment, and education programs, especially in high-prevalence areas.

PROGRESS AND NOTES

- Announced our collaboration with WeightWatchers (WW International Inc.) through which we'll work together to allow our *FreeStyle Libre* continuous glucose monitoring systems and the WeightWatchers mobile app to share information so that people living with diabetes can see their glucose data alongside WeightWatchers' diabetes-tailored program.
 - Delivered the *Future Well Kids* program to more than 2,000 students across five countries. Performed 310 in-person/virtual visits to 73 classrooms and offered a virtual field trip.
 - Partnered with University of the Pacific to develop a sub-specialization in diabetes management within their social work and nursing schools, and provided scholarships for those students committed to working in Stockton, California, post-graduation.
 - Sponsored a pilot initiative designed by the American Diabetes Association with the goal of reducing health inequities and barriers to tools and technology for diabetes management regardless of income level or insurance status.
 - Established the Center for Malnutrition Solutions, a global partnership that focuses on addressing global malnutrition through gathering real-world evidence and applying sustainable, resilient models that address local needs and work to improve access to care.
-
- Received regulatory approvals for *Panbio HIV SELF TEST* in 14 countries. Rapid self-tests enable fast, private, convenient, and accurate testing, enabling people to start treatment earlier. HIV self-testing increases patient autonomy, combats stigma, and can help increase overall testing for HIV.
 - The Abbott Pandemic Defense Coalition, a global network dedicated to identifying emerging viral threats to help prevent future pandemics, expanded its geographic footprint with six new sites: two in the U.S., plus Egypt, Pakistan, Peru, and Sierra Leone. We also contributed to SARS-CoV-2 surveillance, mpox (formerly known as monkeypox) prototype test development, hepatitis biomarker research, national serosurveys, and hepatitis elimination studies. We were recognized in feature stories in both *Bloomberg* and *TIME* magazine, as well as in a *Science* magazine supplement issue.
 - We are a founding member of the Coalition for Global Hepatitis Elimination, contributing funding to create the Hepatitis C Evaluations to Amplify Testing and Treatment (HEAT) program. The program aims to help scale hepatitis testing to meet global elimination goals.

INNOVATE FOR ACCESS AND AFFORDABILITY (CONTINUED)

2030 GOAL

Advance health equity through partnership

Expand affordable access to healthcare for underserved, diverse, and at-risk communities, including women and children, by delivering innovative, decentralized models of care that advance prevention and early diagnosis, improve nutrition, provide quality treatment and care, and lower total costs.

Partner with stakeholders to improve health outcomes by advancing standards and building access to affordable, integrated solutions.

PROGRESS AND NOTES

- Through social investing, shared value, and Abbott Fund programs, provided decentralized healthcare services, helping more than 1 million people access healthcare close to where they live.
 - With support from the Abbott Fund, we launched the Project on Education and Community Health Equity — part of Easterseals Black Child Fund — which aims to address barriers to quality education and healthcare experienced by children and families in under-invested communities.
 - As part of our ongoing partnership with the Tanzanian government, we completed the first models for emergency care at a district hospital emergency department and at a village emergency dispensary. To date, we have helped serve approximately 1.2 million patients in Tanzania.
 - We shifted our disaster response strategy to a “disaster resilience” strategy by providing new “resiliency” grants to four food banks and four health clinics, helping them better prepare for future needs.
 - Established a Diversity in Research Office to further Abbott’s focus on driving diversity within Abbott’s own clinical trials and improving access to care and innovative therapy options among underrepresented populations.
 - Collaborating with Norton Healthcare, Barnett International, and Women as One to develop clinical research infrastructure models for underserved communities and deliver skills training to more physicians, researchers, and clinical research coordinators from diverse communities.
 - Provided funding to help build three new hospitals in Ukraine. These facilities are now equipped and have provided critical services to more than 45,000 people.
-
- Integrated our *Future Well Kids* curriculum into our partnership with the Real Madrid Foundation (RMF). Trained 350 RMF coaches in nine countries and reached more than 12,300 children.
 - Supported launch of the National Association of Community Health Centers (NACHC) Innovation Incubator, aiming to improve health equity by creating innovative solutions to health and digital literacy challenges.
 - Continued our partnership with the Rwandan Ministry of Health and the Society for Family Health in Rwanda to increase access to primary care in rural areas for over 387,000 individuals. Capacity building has enabled treatment of respiratory infections and intestinal parasites, addressing more than 240,000 cases. Additionally, over 79,000 routine malaria tests were administered with over 22,000 cases resolved. In 2022, provided support for health workforce capacity building, enabling 153 health post workers to receive training.

SUSTAINABILITY IN EVERYTHING WE DO

Our 2030 goals also guide actions in our other key areas, including our people, partners, supply chain, and environment. This holistic approach is enabling us to build a more sustainable and resilient business in uncertain times.

2030 GOAL

Build the diverse, innovative workforce of tomorrow

Provide 1 million development and job opportunities for current and future employees.

Create opportunities in Abbott's STEM programs and internships for more than 100,000 young people, including 50% from underrepresented groups.

Continue to drive diversity and inclusion strategies that create a meaningful employee experience and advance Abbott's culture to:

- Achieve gender balance across our global management team with at least 45% female representation
- Achieve gender balance in STEM roles with at least 45% female representation
- Ensure one-third of our leadership roles are held by people from underrepresented groups by 2025
- Continue to drive 100% leadership accountability by tying executive compensation to diversity

PROGRESS AND NOTES

- Created over 346,000 development and job opportunities for current and future employees in 2022, bringing our total to over 509,000 since the launch of our 2030 plan.

- Created over 47,000 STEM opportunities for young people, 64% for people from underrepresented groups in 2022, bringing our total to over 71,000 since the launch of our 2030 plan.
- Launched the HBCU Cybersecurity Industry Collaboration Initiative Pilot with Advancing Minorities' Interest in Engineering (AMIE) and four Historically Black Colleges and Universities (Hampton University, North Carolina A&T State University, Prairie View A&M University, and Virginia State University).
- Expanded our high school STEM internship program into four additional countries — Saudi Arabia, Costa Rica, India, and Canada — bringing the total to eight countries.
- Launched a new skilled-trades apprenticeship program in the U.S. to support electrical, mechanical, and other critical operations/manufacturing roles.

- We continued to work toward building a more inclusive culture, achieving:
 - 41% of global management positions filled by women
 - 45% female representation in STEM roles
 - 35% of leadership roles in the U.S. held by people from underrepresented groups
- Approximately 96% of our people leaders have participated in the Leading With Impact training program, which helps develop stronger managers who cultivate more inclusive teams.
- All Abbott corporate officers, including our Chairman and CEO, carry a Human Capital Metrics goal.

SUSTAINABILITY IN EVERYTHING WE DO (CONTINUED)

2030 GOAL

PROGRESS AND NOTES

Build the diverse, innovative workforce of tomorrow (continued)

Anticipate Abbott's future workforce needs and achieve talent readiness.

- Designed and piloted courses on data-driven decision-making to increase data acumen and agility to adapt to the new world of work. Created an on-demand learning path focused on digital mindset to increase the readiness of our workforce.
- Developed and implemented a nine-week custom-designed Software Engineering Training program to prepare participants to succeed in this field. The program includes mentoring, weekly feedback, and an advisory board with software engineer leadership.

Maintain or improve rates of internal succession for leadership roles.

- 88% of leadership roles filled based on succession plan.

Fill 50% of targeted new jobs with internal talent by upskilling, cross-skilling, and creating learning opportunities.

- 46% of targeted new jobs filled internally.

Continue to provide industry-leading programs that help people achieve their personal health and well-being.

- Launched Spring Health, Abbott's new mental health benefit for U.S. employees and their families.
- Introduced flexible benefits program in Turkey. Employees can select from a list of optional benefits beyond our core medical and insurance offerings.
- Implemented a digital primary care clinic for all employees in Brazil, to improve access to medical care and management of chronic conditions.

Support financial security of employees by helping those with college debt save for retirement, expanding Abbott's *Freedom 2 Save* program by providing \$10 million in matching contributions to participants' retirement accounts.

- Over \$1.7 million total *Freedom 2 Save* employer contributions to participant retirement accounts were made in 2022, bringing our total to over \$5.5 million total employer contributions since program inception in 2019.
- Our Student Loan Payback Program helps Abbott employees in the Netherlands pay off student loans, making it easier to build financial strength. 30,000 euros (approximately \$32,702) in employer contributions have been paid to 20 employee participants since program inception in 2020.

SUSTAINABILITY IN EVERYTHING WE DO (CONTINUED)

2030 GOAL

Responsibly connect data, technology, and care

Be a trusted healthcare leader in secure and responsible data collection, use, management, and privacy, in order to protect our patients and customers, empower them to make better, more complete decisions about their health and drive innovation through insights and analytics.

PROGRESS AND NOTES

- For customers and consumers: Developed and published updated global privacy principles. Achieved 16 ISO/SOC 2 cybersecurity certifications for key connected Abbott products, including Merlin.net, *CardioMEMS*, and *NeuroSphere* Virtual Clinic, providing third-party validation of our security controls. Also launched customer cybersecurity portal to provide healthcare delivery organizations direct access to key cybersecurity information on Abbott products.
- For employees: Enhanced cybersecurity awareness among general employees through key training initiatives and tools, including online modules, phishing simulations, and centrally reporting suspicious emails. And rolled out threat-modeling training for product technical resources and a cyber technical training path.
- For industry: Created and launched the Abbott Medical Device Cybersecurity Council to gain external perspective from expert advisors, including Chief Information Officers (CIOs), Chief Information Security Officers (CISOs), and healthcare providers. Also held a leadership role on the Health Sector Coordinating Council and actively served in other key external cybersecurity and privacy working groups focused on collaboration, standards, and best practice sharing among industry, government, and academia, including the World Economic Forum's Digital Trust Framework, Health-ISAC, and the Medical Device Innovation Consortium.

Create a resilient, diverse, and responsible supply chain

Certify that 80% of newly contracted direct material spends are linked to contracts that incorporate social responsibility requirements.

- We embed social responsibility clauses in applicable procurement contracts detailing our values and expectation that vendors comply with our Supplier Guidelines and remediate identified issues.

Ensure ethical sourcing from all suppliers with high-risk sustainability factors through 100% auditing.

- 88% of direct material suppliers by spend screened for inherent sustainability risk in 2022.
- 260 at-risk suppliers engaged through desktop assessments to evaluate sustainability risks and opportunities in 2022.
- 74 suppliers engaged for sustainability risk through audits in 2022.

SUSTAINABILITY IN EVERYTHING WE DO (CONTINUED)

2030 GOAL

Create a resilient, diverse, and responsible supply chain (continued)

Ensure an inclusive environment by increasing spending with diverse and small businesses 50% by 2030, and Black- and women-owned businesses 150% by 2025, from a 2020 baseline.

PROGRESS AND NOTES

- 88% spend increase from the 2020 baseline with diverse and small businesses.³
- 130% spend increase from the 2020 baseline with Black- and women-owned businesses.³
- Deployed \$2.4 million of the \$37.5 million pledged in growth capital and small business loans to diverse small businesses through our collaboration with Local Initiatives Support Corporation (LISC) since March 2022.
- Partnered with WEConnect International to expand Abbott's global Supplier Diversity Program in Europe, Middle East and Africa, Latin America, and Asia-Pacific.

Protect a healthy environment

Reduce absolute Scope 1 and 2 carbon emissions by 30% from 2018 baseline by the end of 2030, consistent with the objectives of the Science Based Targets initiative (SBTi).

- 5% absolute reduction in Scope 1 and 2 emissions in 2022 (vs. 2018 baseline).
- Abbott's Scope 1 and 2 science-based target was approved by the SBTi in September 2022.
- 80 projects completed, resulting in about 7,000 metric tons of annualized emission reductions.

Abbott commits that 82% of its suppliers by emissions covering purchased goods and services and upstream transportation and distribution will have science-based targets by 2026.

- Approximately 30% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution have science-based targets.⁴
- Abbott's Scope 3 science-based target was approved by the SBTi in September 2022.

Achieve water stewardship certification at all high-water-impact manufacturing sites in water-stressed areas.

- Abbott Granada in Spain and Abbott Temecula in the U.S. are Alliance for Water Stewardship (AWS) Core Certified Sites.⁵

Implement accredited water stewardship management practices in more than 75% of all manufacturing sites operating in water-stressed areas.

- Abbott's accredited water stewardship management practices were finalized in 2022, incorporating feedback from subject matter experts across Abbott.
- All manufacturing sites in water-stressed areas not classified as high impact completed efforts to implement Phase 1 of the accredited water stewardship management practices.

³ Supplier diversity key performance indicators (KPIs) are calculated using the U.S. government fiscal year (October 1 – September 30). Spend data is for U.S. and Puerto Rico for 2022 reporting.

⁴ Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Transportation and Distribution includes Upstream and Downstream. Scope 3 estimations may be adjusted annually to account for data availability and methodology enhancements. Sourcing category spend allocations are subject to change year over year in alignment with business strategy. Abbott's estimated Scope 3 footprint excludes known sources in Downstream Transportation, Processing of Sold Products, Use of Sold Products, and Investment categories. Collectively, these omissions are estimated to represent less than 4% of our total Scope 3 footprint.

⁵ For more information visit a4ws.org/certification.

SUSTAINABILITY IN EVERYTHING WE DO (CONTINUED)

2030 GOAL

Protect a healthy environment (continued)

Work with 50 key suppliers in high water-stressed areas to reduce water quality and quantity risks to Abbott and the community.

Address 50 million pounds of packaging through high-impact sustainable design programs that:

- Employ circularity principles through smart design and material selection
- Eliminate and reduce materials
- Improve the energy efficiency of Abbott's products
- Optimize packaging, pallet, and truckload efficiency

Reduce waste impacts using a circular economy approach, to achieve and maintain at least a 90% diversion rate.

Engage with key suppliers to reduce the environmental impact of materials sent to Abbott that become waste in our operations and develop and track supplier waste diversion initiatives.

PROGRESS AND NOTES

- 29 suppliers operating in water-intense industries and sourcing to Abbott from water-stressed areas assessed to determine water management maturity and water risk engagement opportunities.
- 31% of water-stressed suppliers assessed have set quantitative objectives.
- Five supplier engagements initiated to reduce water quality and quantity risks to Abbott and the community.

- 29.6 million pounds of packaging impacted through sustainable design programs in 2020–2022. This includes:
 - 1.4 million pounds of packaging transitioned to more circular options annually
 - 28.2 million pounds of material eliminated or reduced annually

- 90% waste diversion rate.
- In 2022, two manufacturing facilities and four non-manufacturing facilities received Zero Waste-to-Landfill certification. This brings our total Zero Waste-to-Landfill sites to 51 facilities certified since our program began in 2012.

- A group of identified key suppliers engaged to reduce the environmental impact of materials sent to Abbott that become waste.

SUPPORTING OUR GLOBAL COMMUNITIES

Caring has always been one of our core values. We remain committed to serving the communities where we live and work, supporting them with expertise, products, funding, and volunteer time.

Future Well Communities

Our *Future Well* Communities program in Stockton, California, takes a new approach to removing barriers that prevent people with diabetes from living healthy lives.

Working in close partnership with community groups and leading institutions, our goal is to improve the health of 10,000 people facing the greatest impact of health disparities and diabetes. By providing people with customized, connected health and social services, we're helping them manage their diabetes, build healthy habits and follow healthier diets.

We're also working to build the capacity of the future healthcare workforce by partnering with the University of the Pacific to develop a sub-specialization in diabetes management within their social work and nursing schools. In 2022, the second cohort of 10 Master of Social Work scholars graduated, with nine scholars from the first cohort employed in Stockton. The first cohort of nursing scholars will graduate in May 2024.

Disaster Relief

Abbott and the Abbott Fund are implementing targeted disaster resilience strategies to help prevent and mitigate the impact of hurricanes on communities in New Orleans, Dallas, Orlando, and Puerto Rico, all areas where Abbott has established partnerships with two organizations — Feeding America and Direct Relief — to help communities to prepare for hurricane season. These efforts demonstrated their value in Puerto Rico and Florida when Hurricanes Fiona and Ian hit.

Supporting the Humanitarian Crisis in Ukraine

We have provided almost \$16 million in aid to Ukraine since the war started. This has included \$5 million in grants to International Medical Corps, CARE, Project HOPE, and Americares. We have also donated almost \$11 million in medicines, nutritional products, cardiac devices, and diabetes care products through relief partners and the Ukrainian Ministry of Health.

Employee Giving and Volunteering

Through our comprehensive Employee Giving Program, Abbott:

- Matches employees' donations to eligible nonprofit organizations
- Matches 100% of eligible donations
- Pays all processing fees, so every cent goes to the charity of choice

During the 2022 campaign, 87% of employees in the U.S. and Puerto Rico pledged over \$15 million⁶ to more than 9,300 charitable organizations in a single month.

FUTURE WELL KIDS

Future Well Kids teaches kids about noncommunicable diseases and how they can stay healthy and reduce their risk of developing chronic diseases later in life. During the 2021–2022 school year, the program was delivered to more than 2,000 students, at 23 partner schools, across five countries.

In 2022, we integrated our *Future Well Kids* curriculum into our Real Madrid Foundation partnership, delivering in total, along with our standard curriculum, 11,000 hours of programming to more than 12,300 children in nine countries.



⁶ This figure includes employee donations and Abbott Fund donation matches. It also reflects payroll deduction pledges that are deducted during the 2023 calendar year and may be subject to change based on individual employee decisions.

INNOVATE FOR ACCESS AND AFFORDABILITY

We drive innovation to help ensure people can access the products and services they need to live fuller, healthier lives.

OUR 2022 PROGRESS

>2B

lives improved from Abbott products and services⁷

INTEGRATED

our Innovate for Access and Affordability Design Principles across our businesses

1M+

people globally who were provided decentralized healthcare services

ESTABLISHED

Diversity in Research Office to standardize our approach in clinical trials

6 NEW SITES

added to the Abbott Pandemic Defense Coalition, strengthening our ability to identify viral threats

Abbott is on a mission to improve the lives of 3 billion people a year by 2030. To achieve this, we're designing access and affordability into our products from the start.

We have outlined three Design Principles to embed innovating for access and affordability in how we develop and bring technologies and products to the people who need them:



Design for broader reach and equity:

Build an innovative portfolio that reaches more people, including new geographies and communities with limited access to care.



Design for access:

Identify and overcome barriers to access and adoption, prioritizing inclusive design as well as manufacturing, distribution, and technology strategies to reduce costs across the value chain.



Design to optimize reach and value:

Make intentional decisions throughout the design process to optimize four factors: people reached, consumer benefit, business value, and societal value.

In 2022, we integrated these principles across all of our businesses, helping evolve the way we develop and bring technologies to people who need them.

ACCESS AND AFFORDABILITY THROUGH PRODUCT INNOVATION

Our Design Principles help ensure that we're considering varied perspectives as we develop our products. To help as many people as possible, we know we must work to remove barriers to care for patients around the world. To help ensure we deliver effective, responsible, and equitable solutions, during product development we also consider supply resilience, environmental sustainability, and value.

Affordable, Accessible Diabetes Care With *FreeStyle Libre 3*

Available in Europe since 2020, and cleared by the U.S. Food and Drug Administration (FDA) in 2022 for use by people four years and older living with diabetes (*FreeStyle Libre 3* user manual), our *FreeStyle Libre 3* continuous glucose monitoring (CGM) system enables people to:

- Manage their health in real time — the sensor automatically sends minute-by-minute glucose readings directly to a person's smartphone
- Connect to the *FreeStyle Libre* digital ecosystem for remote monitoring
- Set up alerts for serious medical events⁸

The system is available at the same price as previous generations⁹ — but at one-third the cost of other CGM systems available today.

⁷ Total number of lives improved was adjusted for indirect overlap between businesses using a binomial probability model, and only adjusted for direct overlap within a business where data is currently available to support the adjustment.

⁸ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts; see the *FreeStyle Libre 3* User Manual for more information.

⁹ Based on a comparison of list prices of the *FreeStyle Libre 3* system versus previous generations of *FreeStyle Libre* personal CGM systems.

Saving Time and Money With Revolutionary Plasma Testing for Traumatic Brain Injuries (TBIs)

A 2022 study has uncovered the role two blood-based biomarkers play in predicting recovery following a TBI. Published in *The Lancet Neurology*, the research used Abbott's *i-STAT* TBI Plasma test — and our core laboratory *ARCHITECT* instrument — to test for biomarkers within 24 hours of an injury.

In addition to providing a clearer image of severity, biomarker testing supported predictions of recovery times, long-term implications of the TBI, and optimal treatment plans. The first rapid test on a portable analyzer to receive FDA 510(k) clearance, the *i-STAT* TBI Plasma test can help quickly determine if a more expensive CT scan is needed, saving both time and money during diagnosis. In March 2023, we received FDA clearance for a TBI blood test that runs on our *Alinity* i core laboratory system.

HIV Testing at Home

To make HIV testing more accessible, Abbott launched *Panbio* HIV SELF TEST. Fast, private, and easy-to-use at home, this over-the-counter, fingerstick blood test recognizes patients as positive 1–14 days earlier than previous second-generation tests from exposure to HIV infection.^{10, 11, 12, 13}

Bringing Heart Monitoring Capabilities to More People

In February 2022, Abbott was granted FDA approval to expand use of our *CardioMEMS* HF System, bringing early-stage heart-failure-monitoring technology to a wider pool of patients.

TRANSFORM CARE FOR CHRONIC DISEASE, MALNUTRITION, AND INFECTIOUS DISEASE

Innovating new solutions for disease management is just one aspect of enhancing quality of care. Abbott is also working to expand capabilities in disease detection and prevention. And we're partnering to educate more people on living balanced lives that promote greater health.

Abbott Pandemic Defense Coalition

The Abbott Pandemic Defense Coalition (APDC) was established in 2021 — to stop viruses before they stop us. The coalition, which builds on Abbott's decades-long viral surveillance efforts, is a first-of-its-kind, industry-led partnership that includes 20 scientific and public health organizations on five different continents to identify, track, and respond to known and emerging viral threats to help prevent the next pandemic.

During 2022, representatives from the coalition were invited to the White House to discuss the issue of mpox (formerly known as monkeypox), and how Abbott could help expedite test

production to monitor the spread. We received FDA emergency authorization for mpox tests in the U.S. in October 2022, making Abbott the first company with an authorized test against the pathogen.

New Hope for Treatment-Resistant Depression

In July 2022, we received FDA Breakthrough Device Designation to expedite the review of our deep brain stimulation system and how it can help people living with treatment-resistant depression (TRD). Qualifying for Breakthrough Device Designation highlights the system's potential role in effectively treating an irreversibly debilitating condition. It also enables us to accelerate development, assessment, and review — while maintaining regulatory standards — thereby shortening time to market for our potentially transformational TRD treatment.

a:care — Advancing Medicine Adherence

During 2022, we hosted our second annual a:care Congress, creating a virtual forum for 15,000 healthcare professionals from more than 70 countries to learn more about medication adherence and behavior. Endorsed by over 65 international and national medical societies, the event explored cultural and local factors that can create challenges for adherence and provided practical solutions to help people take charge of their health and live healthier lives by better adhering to their treatment.

¹⁰ Figueroa, C. Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis. *The Lancet HIV* 2018; 5:e277-90; April 24, 2018. [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(18\)30044-4/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30044-4/fulltext)

¹¹ Tonen-Wolyec, S. Field evaluation of capillary blood and oral-fluid HIV self-tests in the Democratic Republic of the Congo. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239607>

¹² Pant Pai, N. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. <https://pubmed.ncbi.nlm.nih.gov/22277215/>

¹³ Stekler, J. Relative accuracy of serum, whole blood, and oral fluid HIV tests among Seattle men who have sex with men. <https://pubmed.ncbi.nlm.nih.gov/24342471/>



Eunice Givens talks with her doctor, vascular surgeon Katherine Kane, M.D., in Fort Worth, Texas.

ADVANCE HEALTH EQUITY THROUGH PARTNERSHIPS

To reach as many people as possible, we must remove barriers standing in the way of good health. We're partnering to decentralize infrastructure and deliver resources tailored to local, real-world needs.

Increasing Representation in Clinical Trials

People from diverse racial, ethnic and cultural backgrounds are disproportionately impacted by some chronic conditions but are underrepresented in clinical trials. This impedes access to life-changing and life-saving treatments, and limits insights into group responses to new therapies.

In 2022, we established a Diversity in Research Office to help standardize our approach to ensuring diverse representation in our own clinical trials when we can.

We also partnered with Norton Healthcare to develop clinical research infrastructure models for underserved communities. And to increase representation and support diverse clinical trialists, we are expanding training for diverse physicians and trial leaders by partnering with Women as One to deliver skills training to female cardiologists. Approximately 40 doctors have participated in the organization's CLIMB training program.

In 2021, we committed \$5 million in scholarships to Historically Black Colleges and Universities (HBCUs) and minority nursing schools. In 2022, we awarded over 50 scholarships.

Supporting Children's Health

In 2021, we signed a three-year agreement to be the Health Sciences and Nutrition Partner for Real Madrid Football Club. We also signed on as Global Partner of the Real Madrid Foundation (RMF), launching our first initiative to tackle malnutrition among children in participating programs.

We also established a three-year partnership with Easterseals to pilot the Project on Education and Community Health Equity, which is creating an integrated system that aims to address barriers to quality education and healthcare experienced in under-invested communities.

Our Longest-Standing Partnership

For more than two decades, Abbott and the Abbott Fund have partnered with the government of Tanzania to strengthen the country's healthcare system. In 2010, Abbott supported development of the country's first emergency medical department at the Muhimbili National Hospital in Dar es Salaam. The department has since trained 79 specialty emergency physicians and more than 6,000 medical, nursing, and paramedic providers — helping approximately 1.2 million patients nationwide.

In 2022, we completed the first models in Tanzania for emergency care at a district hospital emergency department and at a village emergency dispensary in Bantu village. We are now exploring how we can use this partnership as a model for other countries; and our Bantu dispensary as a model for other regions.

RESPONSIBLY CONNECT DATA, TECHNOLOGY, AND CARE

Extraordinary innovation is often powered by technology. Data is changing healthcare — including how, when, and where it is accessed and delivered.

OUR 2022 PROGRESS

PRODUCT CERTIFICATIONS

Achieved 16 cybersecurity certifications for key connected Abbott products, including *Merlin.net*, *CardioMEMS*, and *NeuroSphere Virtual Clinic*

CUSTOMER CYBERSECURITY PORTAL

launched to provide healthcare delivery organizations direct access to key cybersecurity information on Abbott products

ENHANCED TRAINING

on company-wide cybersecurity awareness and skills for key roles

PRIVACY POLICY

updated to align with customer expectations

We believe data and trust go hand in hand, and the people who allow access to their data deserve to have it protected and secured every step of the way. Our goal is to make sure Abbott devices, products, and systems meet the highest security standards, and that commitment guides our approach to data privacy, protection, and ethical data use.

THE PRINCIPLES OF DATA USE

We are committed to protecting data and privacy across our businesses, with three guiding principles:



Transparent

in communicating to people and letting them know how their data will be used



Responsible

in our role in enabling the power of data and also in its appropriate use and protection



Intentional

in how we connect our technology, what data we collect, and how we use it and protect it

Data Privacy and Security

To identify potential privacy and cybersecurity risks, we conduct privacy and security risk assessments and embed data protection into the products and services we design and develop. Our company-wide data protection framework is supported by standards, processes, and training designed to drive compliance, consistency, and employee understanding of the importance of building and maintaining appropriate data

protection controls throughout the product development life cycle.

We draw on multi-stakeholder partnerships to help develop new standards and best practices to remain at the forefront of cybersecurity and privacy leadership. Throughout 2021 and 2022, Abbott supported development of the World Economic Forum's Digital Trust Framework — a resource to establish global consensus on what digital trust means and how it can be achieved.

CONNECTED-CARE TECHNOLOGIES

Connected technologies are key to enabling continuous monitoring capabilities, remote control of healthcare solutions, and improved health outcomes.

In 2022, Abbott launched the next generation of our *NeuroSphere myPath* digital health app. This creates a virtual environment for patients trialing spinal cord stimulation and dorsal root ganglion therapy devices to share responses to chronic pain treatment with their doctors.

And we're enhancing heart monitoring with a suite of connected devices. Our *Gallant* implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices help keep a patient's heart beating normally, while the *Confirm Rx* insertable cardiac monitor enables continuous observation. The *myMerlinPulse* mobile app lets patients track the performance of each device and securely share information with their doctor.

BUILD THE DIVERSE, INNOVATIVE WORKFORCE OF TOMORROW

Our ability to build a healthy, sustainable future depends on the innovative ideas, execution, and dedication of a diverse workforce.

OUR 2022 PROGRESS

41%

of global management positions filled by women

45%

of STEM roles filled by women

35%

of leadership roles in the U.S. held by people from underrepresented groups

88%

of leadership roles filled based on succession plan

46%

of targeted new jobs filled internally

>346,000

development and job opportunities created for current and future employees

>47,000

STEM opportunities created for young people (64% for people from underrepresented groups)

Our talent management approach focuses on attracting, retaining, engaging, and developing a diverse workforce ready for tomorrow's challenges while bringing our strategy to life today.

ATTRACTING THE BEST TALENT

We offer the opportunity to build a great career with financial security and well-being. When you join Abbott, you are part of a community of employees doing purposeful work in an environment where everyone can bring their true self to work every day.

We build and maintain long-term relationships with diverse candidates through the Abbott Talent Community. This helps build a talent pipeline that promotes diversity and longevity.

Retaining and Engaging Our Employees

Our goal is to build a strong pipeline of internal talent through intentional development. This includes offering growth opportunities such as mentoring, leadership training, and personalized career development conversations and tools.

Continuing to Learn and Grow

Our employees can access growth and development opportunities at every stage of their career to build new skills and gain new perspectives. These programs have been designed to support the development and strengthen the skills of all our employees, and to help achieve our goal of increasing diversity in STEM and management roles. By continuing to foster a culture of learning and growth, we will be able to meet the challenges of today and tomorrow and bring our life-changing solutions to more people around the globe.

In 2022, we reinforced the behaviors learned in our Leading With Impact program. Approximately 96% of our people leaders have participated in the training program, which helps develop stronger managers who cultivate more inclusive teams.

Developing Our Future Leaders

Programs to support emerging leaders include our:

- New Leader Program
- GM Acceleration Program
- Global Citizen Development Program
- Operations Leadership Program
- Emerging Leaders Program

In 2022, Abbott filled about 44% of open positions with internal candidates.

Building the Pipeline for Tomorrow

By 2030, Abbott plans to create 100,000 STEM opportunities globally, helping to create a pipeline of talent interested in STEM careers to meet the growing demands for healthcare innovation. We offer a STEM (science, technology, engineering, and math) internship for high school students — particularly for underrepresented applicants — to kick-start their healthcare careers. In 2022, this program was expanded into four additional countries, bringing the total to 23 locations in eight countries to date.

In November 2022, we launched a three-year U.S. skilled-trades apprenticeship program. Apprentices have flexible working hours and study time at nearby community colleges. And they participate in the program while working their full-time job. Abbott's goal is to support apprentices throughout their education while preparing them for long-term careers with us.

EMPLOYEE WELL-BEING

Doing our best work starts with feeling our best. That's why Abbott offers a combination of health, wellness, and life programs that provide security for employees. We also offer opportunities like flextime, part-time hours, compressed work weeks, reduced schedules, job sharing, and remote working.

We continually monitor changing needs and offerings, working to provide innovative programs and a competitive well-being support program. In 2022, for example, we:

- Introduced Spring Health as our new mental healthcare provider for U.S. employees, their covered family members, and everyone in their household
- Implemented a digital primary care clinic for employees in São Paulo, Brazil, to support all Brazilian employees, intended to improve access to medical care and management of chronic conditions
- Offered a flexible benefits program for employees beyond our core medical and insurance offers in Turkey

Financial Well-Being

We work to ensure employees are compensated fairly and without discrimination — regardless of race, ethnicity, or gender. Fair compensation is based on three concepts:

- Base salaries and benefits that are market competitive

- Annual and long-term incentives linked to performance, with a balance of short- and long-term financial and strategic objectives
- Compensation that encourages behavior consistent with the ethical values in Abbott's Code of Business Conduct

Our financial security offerings include several innovative programs designed to address the issues we know employees face.¹⁴

- **Freedom 2 Work:** Developed in the U.S. to allow seasoned employees to reduce their schedules, workloads, and/or responsibilities while continuing to build retirement income.
- **Freedom 2 Save:** Helps U.S. employees save for retirement while repaying student loans.
- **FreeU:** A virtual program to help employees pursue a bachelor's degree on flexible schedules at no personal cost when combined with our tuition reimbursement program.

DIVERSITY, EQUITY, AND INCLUSION

We strive to maintain an inclusive culture where each person can bring their total self to work, and where everyone is valued for their contributions. One way we do this is through our Executive Diversity Council — a group that drives cross-company diversity, equity, and inclusion (DEI) strategy development and implementation. For detailed insights into 2022 workforce diversity, please see our [2022 DEI Report](#).



Abbott's 10 employee networks provide communities of support for colleagues across our company. Here, Samer Saleh (center), a divisional vice president in our Rapid Diagnostics business, connects with Social Media Senior Specialist Shreeya Majmudar (left) and Senior Sales Trainer Ian Wihebrink at an event hosted by our Early Career Network.

¹⁴ Eligibility for non-salary benefits follows local regulations and practices. In most countries, this means we offer benefits to full-time employees and part-time employees working more than a certain number of hours. We typically provide benefit programs above and beyond government requirements.

EMPLOYEE HEALTH AND SAFETY

Keeping employees and contractors healthy and safe is non-negotiable for Abbott. We're committed to driving a culture of shared responsibility, embedding safety considerations throughout our business process.

Our Environmental, Health, and Safety (EHS) Leadership Council is made up of business and global EHS leaders who develop and drive our EHS programs, including those related to employee health and safety.

At the end of 2022, 23 Abbott sites were certified to International Organization for Standardization (ISO) 45001:2018. We regularly update global standards for managing the health and safety of everyone working at Abbott locations.

Each organization must comply with EHS management programs, including:

- Health and safety
- Strategic planning and prioritization
- Risk assessment/self-assessment
- Business integration
- Training and awareness
- Communication and information
- Performance measures

We evaluate commercial operations, manufacturing, and R&D sites on a regular basis. Using an EHS scorecard, senior leadership monitors performance with results used to identify corrective actions.

HUMAN RIGHTS

Our processes for managing human rights risks are embedded throughout the business, encompassing workforce policies, ethics and compliance programs, supply chain management, and more. We regularly evaluate risk exposure, including annual risk assessment of strategic suppliers in our supply chain.

We aim to proactively identify and mitigate potential human rights impacts across our operations and supply chain, including risks of:

- Discrimination and unequal pay
- Unsafe working conditions
- Human trafficking
- Child labor
- Forced or bonded labor

We maintain policies, including our Code of Business Conduct and workplace harassment policy, that reinforce our zero tolerance for any discrimination. They detail steps for reporting instances of workplace harassment or discrimination and clearly define escalation processes. We investigate all reported allegations of harassment or discrimination in a confidential manner and, where necessary, take corrective action.

In our supply chain, we establish human rights expectations of strategic suppliers we enter a business relationship with through our Supplier Guidelines, and conduct assessment, monitoring, and auditing of strategic suppliers to identify and mitigate potential risks, including those related to human rights.



In the summer of 2022, Bhuvi Kedia (left) and Chaya Sandhu (right) gained valuable experience working as high school STEM interns in our diabetes care business.

PROTECT A HEALTHY ENVIRONMENT

As champions for health, we do more than develop life-changing products and technologies. We take targeted action to help protect our environment.

OUR 2022 PROGRESS

SBTi TARGETS

approved for Scope 1, 2, and 3 emissions

5%

absolute reduction in Scope 1 and 2 emissions in 2022 (vs. 2018 baseline)

WATER STEWARDSHIP

certification¹⁵ achieved for two of our high-water-impact sites and internal practices were finalized

INITIATED ENGAGEMENTS

with five water-intense suppliers in water-stressed areas and five suppliers to reduce the environmental impact of materials sent to Abbott that become waste

29M

pounds of packaging impacted through sustainable design programs

90%

waste diversion rate from our operations

We rely on natural resources to manufacture and supply products that help people around the world live healthy, full lives. We are committed to using these resources as responsibly as possible to preserve a healthy environment — now and for future generations. A comprehensive EHS approach and defined governance drive our efforts.

Governance

Abbott's EHS organization reports to the Senior Vice President, Quality Assurance, Regulatory and Engineering Services, who reports to our Chairman and CEO. The Senior Vice President is also the executive sponsor for the development and implementation of our environmental strategy, including climate change and water. The Board of Directors and its committees have oversight over Abbott's environmental, social, and governance practices.

Management Systems and Certifications

We consider Leadership in Energy and Environmental Design (LEED) certification when building new facilities, and have certified 17 projects under LEED standards, including 1 platinum, 4 gold, and 6 silver certifications.

We also consider external certification — such as ISO 14001:2015 — where they add business value. Read more about our environmental management systems and certifications in our 2022 Global Sustainability Report.

2022 ENVIRONMENTAL CERTIFICATIONS

Total sites certified to ISO 50001:2018 and/or ISO 14001:2015	65
Total ISO 14001:2015 Certifications	51
Manufacturing Sites Certified	40
Nonmanufacturing Sites Certified	11
Total ISO 50001:2018 Certifications	30
Manufacturing Sites Certified	18
Nonmanufacturing Sites Certified	12

Environmental Impact Reduction Projects

Our sites regularly establish and deliver projects to address environmental impacts and the unique requirements of their region. Developing facilities for environmental efficiency can also achieve significant financial savings. All figures below are annual and approximate.

- 127 projects completed
- 47 sites across 16 countries
- \$7.5 million expected annual savings
- 27 million kWh annual energy savings and approximately 7,000 metric tons of CO_{2e} emissions reduced
- 6,800 megaliters of water saved
- 1,100 metric tons of waste eliminated


¹⁵ Abbott Granada in Spain and Abbott Temecula in the U.S. are Alliance for Water Stewardship (AWS) Core Certified Sites. For more information visit a4ws.org/certification.

ENERGY AND EMISSIONS

Our energy and air emissions recording and reduction programs are outlined in our Energy Policy, technical standards, and energy guidelines. These activities are supported by and driven through our global EHS Governance team and cross-divisional Energy Council, with a focus on:

- Energy efficiency in manufacturing operations
- Low-carbon energy investments
- Transportation fleet efficiency
- Supply chain carbon footprint

Our Carbon Footprint¹⁸



Emissions Targets Based on Science¹⁶

We are continuing to reduce our emissions as well as strengthen our commitments to reductions for our global operations. In 2022, the Science Based Targets initiative (SBTi) approved Abbott's near-term science-based greenhouse gas (GHG) emission reduction targets and classified our Scope 1 and 2 targets as aligning with a well-below 2°C trajectory.

We aim to reduce absolute Scope 1 and 2 emissions by 30% by 2030 (vs. 2018, target boundary includes land-related emissions and removals from bioenergy feedstock), with a program that targets reductions through:

- Operational energy efficiency and reduced energy demands
- Purchase of renewable energy
- Electrification of industrial processes, spaces, and fleets
- Conversion to cleaner fuel options
- Integration of sustainable engineering technologies and concepts into projects
- Business and manufacturing site-specific carbon reduction goals¹⁷

Scope 3 emissions are estimated annually using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard, referring to the categories¹⁸ applicable to Abbott. We are working with key carbon-intensive suppliers to reduce our Scope 3 footprint. See [page 29](#) for more information on Scope 3 emissions.

Climate Change Adaptation

We're also taking action to protect people's health in a world impacted by climate change, focusing in two areas: tracking and finding solutions for emerging health threats and preparing frontline systems and communities. Across our business and in collaboration with others, we're working to identify and address emerging health issues, strengthen underlying systems, and help build more resilient communities.

Powering Our Facilities

Our ongoing Renewable Energy Procurement initiative drives efforts to increase use of renewables. In 2022, we purchased 180 million kWh of low-carbon and renewable energy, resulting in savings of about 76,500 metric tons of CO₂e. These savings were complemented by the roughly 2.6 million kWh generated from solar installations at 10 of our sites.

We anticipate this value will grow in the future with support from the:

- Launch of our Technical Guideline to Purchasing Renewable Energy, intended to guide and encourage sites to increase efforts in renewable energy procurement
- Three additional sites that received Abbott funding in 2022 to install on-site solar panels

See our TCFD index in the Abbott 2022 Global Sustainability Report for details of climate-related risks and disclosures.

¹⁶ Scope 1 emissions result from owned and controlled sources. Scope 2 emissions are produced during generation of purchased electricity and energy.

¹⁷ Manufacturing sites that produce over 25,000 metric tons of CO₂e annually are required to set additional carbon reduction goals.

¹⁸ Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Transportation and Distribution includes Upstream and Downstream. Scope 3 estimations may be adjusted annually to account for data availability and methodology enhancements. Sourcing category spend allocations are subject to change year over year in alignment with business strategy. Abbott's estimated Scope 3 footprint excludes known sources in Downstream Transportation, Processing of Sold Products, Use of Sold Products, and Investment categories. Collectively, these omissions are estimated to represent less than 4% of our total Scope 3 footprint.

PROTECTING WATER RESOURCES

Wherever we use and discharge water, we work to minimize the impact we have on the quality and quantity of local sources. In some instances, we have established initiatives that address the most pressing local needs for those who rely on this precious natural resource.

Our water management approach centers around four principles:

- **Reduce:** Continuously work to improve water use efficiency in our operations.
- **Prevent:** Manage water discharges that could adversely impact human health or the environment.
- **Educate:** Emphasize the importance of protecting vulnerable water resources and the role our employees and suppliers play in doing so.
- **Engage:** Develop and apply key water management principles and best practices across our company.

We use a context-based approach to water management, annually assessing for resilience, using the World Resource Institute (WRI) Aqueduct™ tool to analyze local water stress and evaluate against our internal water use intensity. This analysis allows us to tailor our water management systems accordingly.

Water Stewardship

We took concerted efforts throughout 2022 to reduce our water use and impacts. Total water intake in 2022 decreased by 0.2% versus the previous year. When adjusted for sales, water intake decreased by 1.5% compared to 2021.

WASTE MANAGEMENT

Our waste management strategy commits us to finding ethical, economical, and efficient ways to reduce the volume and hazardous characteristics of our waste and use proper disposal practices. It also goes further, with a commitment to maximize recovery of resources and improve operating efficiency while reducing environmental risks and impacts.


We work to reduce the impact of our products and services — including the waste they produce — throughout the life cycle:

- **Procurement:** We engage strategic suppliers to ensure operational inputs — e.g., raw materials, processed goods, and services — are procured ethically and sustainably.
- **Design, production, and distribution:** We consider the environmental and social impacts of how we produce and deliver our products.
- **Consumption:** We aim for our products to be consumed and disposed of in environmentally responsible ways.


Efforts to manage and reduce our waste footprint are supported by safe material handling training for relevant manufacturing workers.

OUR OPERATIONAL WASTE FOOTPRINT

WASTE GENERATED IN 2022



BENEFICIAL USE IN 2022¹⁹



¹⁹ Abbott defines beneficial-use activities as sending material that otherwise would have been waste off-site to be used as an effective substitute for a commercial product or commodity. Beneficial-use material is used as is or in substantially the same form as it was generated.

PACKAGING

Recognizing the impact our packaging can have on the environment, we're designing for recyclability, efficiency, and increasingly positive impact. Our Sustainable Packaging Council has designed a database for reporting predicted progress against division projections for packaging projects. These next-decade figures guide Abbott functions as they collaborate to design and manufacture packaging with environmental sustainability as a priority.

Our 2030 commitment is to address 50 million pounds of packaging through high-impact sustainable design programs that employ circularity principles. Sustainable Packaging Guiding Principles inform existing packaging upgrades and target new, more sustainable designs.

Since 2020, 29.6 million pounds of packaging have been impacted by our sustainable design programs. This includes the transition of 1.4 million pounds of packaging to more circular options and the elimination of 28.2 million pounds of material annually.

Working With Our Suppliers

We're engaging suppliers in our efforts to lower the impact of packaging as part of our circular economy approach. Throughout 2022, we worked with five key suppliers to reduce the environmental impacts of inbound materials, discussing mutually beneficial opportunities to prevent them becoming waste.

Sustainable Packaging Project Roadmap

In July 2022, we established a detailed three-year roadmap for sustainable packaging. The guide includes investment required and a KPI tracking system for our 2030 packaging commitment. Projects focus on the optimization of existing packaging and institutionalizing sustainable packaging design for new projects.

Lightweight *BinaxNOW* Packaging

Part of optimizing our packaging is finding ways to do more with less material. In 2022, we initiated a total package redesign to reduce package weight and materials, as well as improve transport efficiency.

Abbott's Rapid Diagnostics business launched the *BinaxNOW* home-use COVID-19 test kit under extraordinary circumstances in December 2020. Its packaging has since been optimized and is now up to 27% smaller and 58% lighter.

The team achieved this by:

- Consolidating two information sheets into one
- Eliminating a high-impact-polystyrene tray
- Resizing the paperboard carton and corrugated case

With more than 497 million *BinaxNOW* tests manufactured in 2022, these changes eliminated approximately 26.7 million pounds of packaging, including more than 9.8 million pounds of plastic (savings based on annualized reductions).

RESPONSIBLE SOURCING AND PRODUCT STEWARDSHIP

We work with key supply chain partners to understand the wider effects of our products. These partnerships inform stewardship by providing insight into every step of the product life cycle.

Our Product Stewardship, Supply Chain, R&D, Engineering, and EHS groups collaborate to analyze how, and what, we source. Relevant teams partner to identify and mitigate environmental impacts of our packaging and products.

To help ensure compliance with applicable regulations, our product stewardship work focuses on minimizing the use of hazardous chemicals and substances of concern, and managing these materials in products, packaging, and manufacturing processes. When substances are identified, risk assessments are prepared, following evaluation of:

- Whether continued use can be justified
- The value of use versus reformulation
- Any potential compliance issues

The evaluation process creates an opportunity to research suitable alternatives, including potential product performance and cost impacts. Business management reviews recommendations for next steps, including justification for substance use, product support strategies, and business risk monitoring and mitigation plans.

QUALITY MANAGEMENT

Every day, people around the world rely on Abbott to provide life-changing products and services. Delivering high-quality, safe, and effective products and technologies is fundamental to our business.

ESTABLISHING A CULTURE OF QUALITY

Maintaining quality requires a company-wide commitment. That's why we work to embed it across our company.

We have robust quality processes in place for all of our products, and we are committed to continually assessing and improving those processes as information, technologies, and practices evolve. We also work with our suppliers to promote the same commitment to quality and safety, through qualification programs, audits, and other tools.

We maintain over 20 quality focused working groups led by our global subject matter experts, who delve into emerging issues and learnings from events to improve practices and processes.

Quality Management System

Abbott's Quality Management System (QMS) model and metrics are continuously reviewed to track site, business, and company-level performance. We capture and apply key learnings and best practices, including those from external intelligence, and industry-specific issues are examined and escalated as appropriate. We analyze root causes for performance indicators and take appropriate corrective actions. In targeted use cases, machine learning enhances potential risk predictions. To enhance data analysis and decision-making, the Abbott Quality and Regulatory (AQR) advanced analytics team is increasingly harnessing machine learning and artificial intelligence to modernize processes.

We conduct compliance auditing at the site, division, and corporate levels. Each operating business maintains a QMS and performs audits in line with governing regulations. Surveillance results feed into continuous improvement initiatives.

Our quality system is based on established regulations and industry standards that govern the quality framework for Abbott businesses. We have policies, processes, and procedures that encompass the total product life cycle, including the design of cybersecurity controls, to help ensure quality design at every stage.

Our operations cross several jurisdictions, with 88 manufacturing sites and oversight from over 120 quality and regulatory agencies. Our quality framework drives regulatory compliance wherever we operate.

New employees are trained on QMS elements, with an annual QMS refresher course delivered to existing and part-time personnel.

Independent Quality Certifications

Manufacturing operations hold Good Manufacturing Practices (GMP) certification, including ISO 13485 certification and ISO 9001 certification for quality management. One hundred percent of Abbott's finished device manufacturing sites have been certified under ISO 13485. Of our international nutrition manufacturing sites, 83% are ISO 9001 certified and 100% are ISO 22000 certified. Abbott's Quality Manual and QMS encompass the requirements of the ISO standards and are implemented at all manufacturing sites. Our nutrition manufacturing maintains Food and Safety standards certification as well.

Across Abbott, our sites hold various certifications,²⁰ including:

- ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO/IEC 17025:017 and ISO 22000:2018
- NSF (National Sanitation Foundation) International
- GMP+ FSA (Good Manufacturing Practices Plus and Food Safety Assurance)
- HACCP (Hazard Analysis and Critical Control Points)
- AAMI (Association for the Advancement of Medical Instrumentation)
- ASTM International
- ISPE (International Society for Pharmaceutical Engineering)

²⁰ This list represents a sample of the standards our sites maintain and that are frequently used as indicators of product quality.

CREATE A RESILIENT, DIVERSE, AND RESPONSIBLE SUPPLY CHAIN

Abbott manages our supply chain to amplify our positive impact on the world.

OUR 2022 PROGRESS

88%

spend increase from the 2020 baseline with diverse and small businesses²¹

130%

spend increase from the 2020 baseline with Black and women-owned businesses²¹

3,900+ SUPPLIERS

engaged on sustainability risks and opportunities

For our work with suppliers to lower their environmental impacts, please see the Environment section of our 2022 Global Sustainability Report.

Our global supplier network enables us to deliver life-changing products to millions of people around the world.



Approximately
89,000
suppliers



Across
163 countries



In 2022, we spent
approximately
\$23B with
these suppliers

GOVERNANCE

With a global footprint, we have an opportunity to leverage our supply chain for positive social and environmental change. We maintain a multi-layered governance structure that provides oversight of supply chain-related activities, helping minimize risks and maximize opportunities to address shared impacts.

Our management approach places particular importance on supply chain sustainability and resilience. Each Abbott business is responsible for its respective supply chain, with enterprise efforts coordinated through our Global Operations Council (GOC). The GOC collaborates across the enterprise to set the framework for our supply chain, encompassing procurement, manufacturing, and logistics to improve supply chain adaptability, resilience, and flexibility.

DESIGNING FOR SUPPLY CHAIN RESILIENCE

Decisions made early in product development impact later stages. To help safeguard our ability to manufacture and supply products after launch, we've enhanced collaboration between R&D and Supply Chain teams to reduce dependence on individual suppliers or bespoke manufacturing processes.

Through our Design for Supply initiative, we're developing Design Principles, tools, and supplier engagement models that address our needs throughout the product development life cycle. This allows Abbott to be more resilient in dynamic market conditions.

GUIDING RESPONSIBLE SUPPLIERS

We are committed to upholding the fundamental principles of environmental protection and human rights and labor to drive long-term business success for Abbott and our suppliers, and to improve lives around the world.

Our Supplier Guidelines establish expectations for suppliers we work with, aligning with internationally recognized and industry-accepted guidelines, such as the Pharmaceutical Supply Chain Initiative (PSCI) Principles for Responsible Supply Chain Management. Our Guidelines focus on the following priorities: management systems, human rights and labor, health and safety, ethics, environmental management and compliance, and supply chain management.

²¹ Supplier diversity key performance indicators (KPIs) are calculated using the U.S. government fiscal year (October 1 – September 30). Spend data is for U.S. and Puerto Rico for 2022 reporting. 2022 target for annual spend of small and diverse suppliers is \$3.27 billion.

SUPPLIER-SUSTAINABILITY-RISK DUE DILIGENCE PROGRAM

We maintain a formal supplier assessment process to minimize reputational and continuity risks and monitor compliance with our Supplier Guidelines.

Our Supply Chain Resilience program helps further safeguard our business and supply chain against unforeseen events; developing people, processes, and tools for engaging suppliers on identified topics. We have updated this program to help standardize how we monitor and measure events across the supply chain. Nineteen risk metrics and 13 resilience indicators guide how we assess topics at different supply, product, or business points.

In 2022, we continued partnering with suppliers from key sourcing categories, engaging over 3,900 suppliers on sustainability risks and opportunities and influencing over 49% of our supply chain spend. These activities addressed 260 potential high-sustainability-risk suppliers through desktop assessments and 74 high-sustainability-risk suppliers through sustainability audits.

Through our 2022 audit programs, we engaged with seven suppliers to implement corrective actions to address employee health and safety, environment, and supply chain management issues.

STRENGTHENING THE SUPPLY CHAIN

We partner with strategic suppliers to address shared sustainability impacts, prioritizing responsible sourcing, supplier diversity, and continuity of supply.

Strategic Supply Chain Initiatives

Our supply chain initiatives prioritize topics such as labor, human rights, environment, and anti-corruption, and drive collective action. This is achieved through issue-specific initiatives, which cover the whole supply chain and address targeted topics, such as supplier diversity and emissions, water, and inbound materials management, and through sourcing category-, business-, and region-specific initiatives, which cover multiple risks and opportunities in high-sustainability-risk areas.

Collaborating for Supplier Diversity

In 2022, we announced a partnership with the Local Initiatives Support Corporation, a nonprofit committed to connecting under-invested people and places to private resources. Starting in 2022, we pledged \$37.5 million in investments for diverse small business in the U.S., splitting funding across growth capital grants, business loans, and technical assistance. To date, we have engaged with over 370 businesses through the initiative and have invested \$2.4 million in growth capital and business loans to diverse suppliers.

Supply Chain Water Risks

In 2021, we completed a supply chain assessment to identify and prioritize supplier engagements for the coming years. This process identified 52 suppliers who operate in water-intensive or -impactful industries and source to Abbott from water-stressed locations in 2022. Of the identified suppliers, 29 suppliers operating in water-intense industries and sourcing to Abbott from water-stressed areas were assessed to determine water-management maturity and water-risk engagement.

Supply Chain Emissions Management¹⁸

Scope 3 emissions account for more than 90% of Abbott's carbon footprint. A cross-functional team identifies our most carbon-intensive suppliers and sourcing categories with the greatest emission reduction opportunities.

As part of our 2030 strategy, Abbott committed to engage our key carbon-intensive suppliers to implement sustainable programs to reduce our Scope 3 emissions. In 2022, the SBTi approved Abbott's Scope 3 target, in which we commit that 82% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution will have science-based targets by 2026.

As of 2022 year end, approximately 30% of our suppliers by emissions covering purchased goods and services and upstream transportation and distribution have SBTi approved science-based targets, with about an additional 14% committing through the SBTi to adopt science-based targets.

¹⁸ Abbott estimates Scope 3 emissions using the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Transportation and Distribution includes Upstream and Downstream. Scope 3 estimations may be adjusted annually to account for data availability and methodology enhancements. Sourcing category spend allocations are subject to change year over year in alignment with business strategy. Abbott's estimated Scope 3 footprint excludes known sources in Downstream Transportation, Processing of Sold Products, Use of Sold Products, and Investment categories. Collectively, these omissions are estimated to represent less than 4% of our total Scope 3 footprint.

ETHICS AND COMPLIANCE

To help create the future of healthcare, we must continually build on the trust Abbott has earned over our 135-year history. We aim to innovate accessible, affordable solutions that transform lives, and to do so sustainably. Robust governance helps ensure we have the leadership, policies, and structures in place to succeed.

GLOBAL ETHICS AND COMPLIANCE PROGRAM

Upholding ethical practices and ensuring we comply with relevant regulations is how Abbott demonstrates its commitment to responsible business practices. Our global ethics and compliance program — which is regularly reviewed by an external party — reflects the fundamental elements of an effective corporate compliance program as detailed in the Office of Inspector General guidance and U.S. Federal Sentencing guidelines.

Read more about Governance and Sustainability Foundations in the Abbott 2022 Global Sustainability Report.

Clear Leadership and Accountability

Abbott's Chief Ethics and Compliance Officer (CECO) is the corporate officer responsible for leading our ethics and compliance program and managing our Office of Ethics and Compliance (OEC). The CECO provides regular briefings to our Chairman and CEO, executive leaders, Board of Directors, and the Public Policy Committee.

Written Standards of Conduct

Our Code of Business Conduct, available in 29 languages, is foundational to ethical conduct at Abbott. Every employee is required to read and certify adherence to the code annually. It outlines our company values and the expectation for our employees to live them every day.

Processes for Reporting Concerns

Our code emphasizes employees' responsibility to report concerns of noncompliance. We have defined avenues and processes for asking questions and reporting suspected or actual violations of our code, policies, or procedures. These include our 24/7 Speak Up tool, through which employees and external parties can confidentially and — where permitted — anonymously raise concerns of potential misconduct. Abbott has a strict policy against retaliation in any form for reporting concerns.

Rigorous Auditing and Monitoring

OEC personnel supporting each Abbott business unit and country perform an annual risk assessment to identify areas of potential compliance risk. Based on assessment outcomes, they then establish monitoring plans for the year, which includes selecting a risk-based sampling of interactions with healthcare providers and reviewing supporting documentation to assess

compliance with Abbott's policies. Abbott conducts sales and marketing compliance audits of global operations to assess compliance with ethics and compliance standards.

Processes for Investigations and Corrective Actions

All reports of potential code violations — including those related to discrimination and harassment — by employees and third parties who perform certain services on our behalf are thoroughly investigated. Any employee violating our Code of Business Conduct, policies, or procedures is subject to appropriate disciplinary action, which may include termination. Employees refusing to cooperate in investigations — or knowingly reporting false concerns, or ones intended to threaten, intimidate, or retaliate — may also be subject to disciplinary action.

Risk Assessments to Enhance Compliance

Our OEC has embedded risk assessment into Abbott's global compliance program. It oversees periodic compliance risk assessments and monitors the external risk environment. Factors assessed by the OEC include evolving industry best practices, government guidance, and enforcement actions taken against other companies.

Company-wide Training and Communications

Offered in 93 countries and available in 32 languages, our online Legal and Ethical Resource Network (LERN) training educates employees on our Code of Business Conduct. The LERN program also shares practical guidance on recognizing and responding to legal and ethical issues. In 2022, over 99.7% of active employees completed the annually assigned Code of Business Conduct training course and certification.

SUSTAINABILITY REPORTING

We have aligned our reporting with the requirements of leading ESG ratings and sustainability indices, seeking stakeholder feedback to drive continuous improvement. Our detailed annual reports can be found at our Abbott Sustainability Hub and are listed here:

- [Global Sustainability Report](#)
- [Diversity, Equity, and Inclusion Report](#)
- [GRI Index](#)
- [SASB Index](#)
- [TCFD Index](#)
- [UN SDG Index](#)

Totals and percentage changes may differ from listed metrics due to rounding. To ensure data accuracy, the most accurate numbers have been used.

²² These percentages are as of December 31. Percentages represent a count of U.S. employees, excluding the Rapid Diagnostics business.

²³ Abbott Fund, Citizenship, business contributions, and product donations.

²⁴ 2021 marked the first year of our enhanced Employee Giving Program. See page 23 of our Abbott 2022 Global Sustainability Report.

²⁵ Per our environmental, health, and safety metrics reporting protocols, metrics data published in previous years were adjusted in this report to reflect minor corrections, method adjustments, etc. We report data from acquisitions as soon as is practical. Additionally, in 2022, we aligned key environmental metrics data presented in the Abbott 2022 Global Sustainability Report Appendix with GRI specified units, where possible.

²⁶ Scope 2 emissions are calculated using the Greenhouse Gas Protocol (GHGP) market-based methodology. Per the GHGP, where market-based information is not available, location-based results have been used as proxy.

²⁷ Water withdrawal is equivalent to water intake.

²⁸ Waste-generation data does not include materials that are reused beneficially.

²⁹ Abbott defines beneficial-use activities as sending material that otherwise would have been waste off-site to be used as an effective substitute for a commercial product or commodity. Beneficial-use material is used as is or in substantially the same form as it was generated.

³⁰ This is the baseline year.

FINANCIAL AND SOCIAL METRICS

SALES WORLDWIDE

	Dollars in Millions
2022	\$43,653
2021	\$43,075
2020	\$34,608
2019	\$31,904

EMPLOYEES

	Total	% of Management Who Are Women (U.S.) ²²	% of Management Who Are Minorities (U.S.) ²²
2022	115,000	43%	35%
2021	113,000	43%	33%
2020	109,000	42%	32%
2019	107,000	41%	36%

SOCIAL INVESTING²³

	Dollars in Millions
2022	\$74.2
2021	\$90.1
2020	\$75.7
2019	\$70.6

U.S. EMPLOYEE GIVING CAMPAIGN RESULTS²⁴

	Dollars in Millions
2022	\$15.10
2021	\$15.00
2020	\$7.58
2019	\$6.71

ENVIRONMENTAL METRICS²⁵

SCOPE 1 AND 2 CARBON EMISSIONS INTENSITY – NORMALIZED TO SALES

	1,000 Metric Tons CO ₂ e per \$ Million Sales				
	Total (Scope 1 and 2) Market-Based CO ₂ e Emissions ²⁶	Total (Scope 1 and 2) Location-Based CO ₂ e Emissions	Total Direct (Scope 1) CO ₂ e Emissions	Purchased Energy (Scope 2) Market-Based CO ₂ e Emissions ²⁶	Purchased Energy (Scope 2) Location-Based CO ₂ e Emissions
2022	21	23	12	9	11
2021	22	24	12	9	11
2020	26	28	14	12	14
2018 ³⁰	32	35	18	15	17

WATER WITHDRAWAL INTENSITY – NORMALIZED TO SALES²⁷

	Megaliters per \$ Million Sales
2022	0.32
2021	0.32
2020	0.38
2019	0.42

TOTAL WASTE INTENSITY – NORMALIZED TO SALES²⁸

	Metric Tons per \$ Million Sales
2022	1.5
2021	1.6
2020	1.8
2019	2.0

BENEFICIAL USE²⁹

	Metric Tons
2022	107,131
2021	110,301
2020	96,972
2019	114,770



life. to the fullest.®

Abbott

Abbott Sustainability
100 Abbott Park Road
Department 0383
Abbott Park, IL 60064-6048

responsibility@abbott.com

www.abbott.com/sustainability